One donor, two transplants: new approach for patients with dual diseases
NCT ID NCT07358195
Summary
This early-phase study is testing the safety of adding a drug called venetoclax to a combined transplant procedure. It is for a very small group of patients who have both a blood cancer that may be cured by a stem cell transplant and advanced kidney failure requiring a kidney transplant. The goal is to see if using this drug makes the combined transplant safer and more effective by helping the patient's body accept the donor cells and kidney.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.